288 related articles for article (PubMed ID: 34052230)
1. Virological and clinical outcomes in outpatients treated with baloxavir or oseltamivir: A Japanese multicenter study in the 2019-2020 influenza season.
Chong Y; Kawai N; Tani N; Bando T; Takasaki Y; Shindo S; Ikematsu H
Antiviral Res; 2021 Aug; 192():105092. PubMed ID: 34052230
[TBL] [Abstract][Full Text] [Related]
2. Duration of fever and symptoms in children after treatment with baloxavir marboxil and oseltamivir during the 2018-2019 season and detection of variant influenza a viruses with polymerase acidic subunit substitutions.
Saito R; Osada H; Wagatsuma K; Chon I; Sato I; Kawashima T; Saito T; Kodo N; Ono Y; Shimada Y; Phyu W; Shobugawa Y
Antiviral Res; 2020 Nov; 183():104951. PubMed ID: 32987032
[TBL] [Abstract][Full Text] [Related]
3. Virological and clinical outcomes in outpatients treated with baloxavir or neuraminidase inhibitors for A(H3N2) influenza: A multicenter study of the 2022-2023 season.
Goto T; Kawai N; Bando T; Takasaki Y; Shindo S; Tani N; Chong Y; Ikematsu H
Antiviral Res; 2024 Apr; 224():105853. PubMed ID: 38430970
[TBL] [Abstract][Full Text] [Related]
4. Duration of fever and symptoms in influenza-infected children treated with baloxavir marboxil during the 2019-2020 season in Japan and detection of influenza virus with the PA E23K substitution.
Wagatsuma K; Saito R; Chon I; Phyu WW; Fujio K; Kawashima T; Sato I; Saito T; Minato M; Kodo N; Suzuki E; Ono Y; Masaki H; Shirahige Y; Kitano A; Hamabata H; Yuyang S; Jiaming L; Watanabe H
Antiviral Res; 2022 May; 201():105310. PubMed ID: 35358601
[TBL] [Abstract][Full Text] [Related]
5. Duration of fever and PA/I38X-substituted virus emergence in patients treated with baloxavir in the 2018-2019 influenza season.
Ikematsu H; Kawai N; Tani N; Chong Y; Iwaki N; Bando T; Tanaka O; Matsuura S; Maeda T; Doniwa K
J Infect Chemother; 2020 Apr; 26(4):400-402. PubMed ID: 31870588
[TBL] [Abstract][Full Text] [Related]
6. Detection of Variants With Reduced Baloxavir Marboxil Susceptibility After Treatment of Children With Influenza A During the 2018-2019 Influenza Season.
Sato M; Takashita E; Katayose M; Nemoto K; Sakai N; Hashimoto K; Hosoya M
J Infect Dis; 2020 Jun; 222(1):121-125. PubMed ID: 32034420
[TBL] [Abstract][Full Text] [Related]
7. Detection of Variants With Reduced Baloxavir Marboxil and Oseltamivir Susceptibility in Children With Influenza A During the 2019-2020 Influenza Season.
Sato M; Takashita E; Katayose M; Nemoto K; Sakai N; Fujisaki S; Hashimoto K; Hosoya M
J Infect Dis; 2021 Nov; 224(10):1735-1741. PubMed ID: 33837427
[TBL] [Abstract][Full Text] [Related]
8. Baloxavir for the treatment of Influenza in allogeneic hematopoietic stem cell transplant recipients previously treated with oseltamivir.
Salvatore M; Laplante JM; Soave R; Orfali N; Plate M; van Besien K; St George K
Transpl Infect Dis; 2020 Aug; 22(4):e13336. PubMed ID: 32449254
[TBL] [Abstract][Full Text] [Related]
9. Global update on the susceptibilities of human influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2018-2020.
Govorkova EA; Takashita E; Daniels RS; Fujisaki S; Presser LD; Patel MC; Huang W; Lackenby A; Nguyen HT; Pereyaslov D; Rattigan A; Brown SK; Samaan M; Subbarao K; Wong S; Wang D; Webby RJ; Yen HL; Zhang W; Meijer A; Gubareva LV
Antiviral Res; 2022 Apr; 200():105281. PubMed ID: 35292289
[TBL] [Abstract][Full Text] [Related]
10. Baloxavir treatment of oseltamivir-resistant influenza A/H1pdm09 in two immunocompromised patients.
Macesic N; Laplante JM; Aaron JG; DiMango EA; Miko BA; Pereira MR; Reshef R; St George K
Transpl Infect Dis; 2021 Jun; 23(3):e13542. PubMed ID: 33278052
[TBL] [Abstract][Full Text] [Related]
11. Clinical effectiveness of baloxavir marboxil against influenza in three seasons.
Kakuya F; Okubo H; Fujiyasu H; Kurisawa MJ; Kinebuchi T
Pediatr Int; 2022 Jan; 64(1):e15169. PubMed ID: 35790049
[TBL] [Abstract][Full Text] [Related]
12. Effect of Baloxavir and Oseltamivir in Combination on Infection with Influenza Viruses with PA/I38T or PA/E23K Substitutions in the Ferret Model.
Koszalka P; George A; Dhanasekaran V; Hurt AC; Subbarao K
mBio; 2022 Aug; 13(4):e0105622. PubMed ID: 35938724
[TBL] [Abstract][Full Text] [Related]
13. Impact of the Baloxavir-Resistant Polymerase Acid I38T Substitution on the Fitness of Contemporary Influenza A(H1N1)pdm09 and A(H3N2) Strains.
Checkmahomed L; M'hamdi Z; Carbonneau J; Venable MC; Baz M; Abed Y; Boivin G
J Infect Dis; 2020 Jan; 221(1):63-70. PubMed ID: 31419295
[TBL] [Abstract][Full Text] [Related]
14. Influenza A(H1N1)pdm09 virus exhibiting reduced susceptibility to baloxavir due to a PA E23K substitution detected from a child without baloxavir treatment.
Takashita E; Abe T; Morita H; Nagata S; Fujisaki S; Miura H; Shirakura M; Kishida N; Nakamura K; Kuwahara T; Mitamura K; Ichikawa M; Yamazaki M; Watanabe S; Hasegawa H;
Antiviral Res; 2020 Aug; 180():104828. PubMed ID: 32574689
[TBL] [Abstract][Full Text] [Related]
15. Global update on the susceptibilities of human influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2017-2018.
Takashita E; Daniels RS; Fujisaki S; Gregory V; Gubareva LV; Huang W; Hurt AC; Lackenby A; Nguyen HT; Pereyaslov D; Roe M; Samaan M; Subbarao K; Tse H; Wang D; Yen HL; Zhang W; Meijer A
Antiviral Res; 2020 Mar; 175():104718. PubMed ID: 32004620
[TBL] [Abstract][Full Text] [Related]
16. Comparison of Hospitalization Incidence in Influenza Outpatients Treated With Baloxavir Marboxil or Neuraminidase Inhibitors: A Health Insurance Claims Database Study.
Komeda T; Takazono T; Hosogaya N; Miyazaki T; Ogura E; Iwata S; Miyauchi H; Honda K; Fujiwara M; Ajisawa Y; Watanabe H; Kitanishi Y; Hara K; Mukae H
Clin Infect Dis; 2021 Sep; 73(5):e1181-e1190. PubMed ID: 33354728
[TBL] [Abstract][Full Text] [Related]
17. Clinical efficacy and safety of baloxavir marboxil in the treatment of influenza: A systematic review and meta-analysis of randomized controlled trials.
Kuo YC; Lai CC; Wang YH; Chen CH; Wang CY
J Microbiol Immunol Infect; 2021 Oct; 54(5):865-875. PubMed ID: 34020891
[TBL] [Abstract][Full Text] [Related]
18. A Comparison of the Frequency of Prescription and Pharmacy Revisits between Baloxavir Marboxil and Neuraminidase Inhibitors in Influenza-Infected Pediatric Patients during the 2019-2020 Influenza Season.
Norikoshi Y; Ikeda T; Sasahara K; Hamada M; Torigoe E; Nagae M; Tashiro T; Horio F; Saruwatari J; Uchida Y; Anraku M
Biol Pharm Bull; 2020; 43(12):1960-1965. PubMed ID: 33268716
[TBL] [Abstract][Full Text] [Related]
19. Clinical and virological outcomes with baloxavir compared with oseltamivir in pediatric patients aged 6 to < 12 years with influenza: an open-label, randomized, active-controlled trial protocol.
Ishiguro N; Morioka I; Nakano T; Furukawa M; Tanaka S; Kinoshita M; Manabe A
BMC Infect Dis; 2021 Aug; 21(1):777. PubMed ID: 34372769
[TBL] [Abstract][Full Text] [Related]
20. Baloxavir Marboxil 2% Granules in Japanese Children With Influenza: An Open-label Phase 3 Study.
Yokoyama T; Sakaguchi H; Ishibashi T; Shishido T; Piedra PA; Sato C; Tsuchiya K; Uehara T
Pediatr Infect Dis J; 2020 Aug; 39(8):706-712. PubMed ID: 32433222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
